BACKGROUND: Because the development of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSA) after lung transplantation has been associated with acute and chronic rejection, we implemented a clinical protocol to screen all transplant recipients for DSA and preemptively treat those who developed DSA withrituximab and intravenous immune globulin (IVIG), or IVIG alone. METHODS: We conducted a prospective observational study of this protocol and used the LABScreen Single Antigen assay to detect DSA after transplantation. We compared the incidence of acute rejection, lymphocytic bronchiolitis, and bronchiolitis obliterans syndrome (BOS) between those who developed DSA and those who did not using Cox proportional hazards models. We used the Kaplan-Meier method to compare freedom from BOS and survival between those who had persistent DSA and those who had successful depletion of DSA. RESULTS: Among 116 recipients screened, DSA developed in 65 during the study period. Those who developed DSA and received antibody-directed therapy had a similar incidence of acute rejection, lymphocytic bronchiolitis, and BOS as those who did not develop DSA. Furthermore, recipients who had successful depletion of DSA had greater freedom from BOS and better survival than those who had persistent DSA. Finally, those treated for DSA had a similar incidence of infectious complications as those who did not develop DSA. CONCLUSIONS: The development of DSA is surprisingly common after lung transplantation. Antibody-directed therapy may reduce the risk of rejection associated with DSA, but a randomized controlled trial is necessary to critically evaluate the efficacy of this treatment protocol. Copyright2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
RCT Entities:
BACKGROUND: Because the development of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSA) after lung transplantation has been associated with acute and chronic rejection, we implemented a clinical protocol to screen all transplant recipients for DSA and preemptively treat those who developed DSA with rituximab and intravenous immune globulin (IVIG), or IVIG alone. METHODS: We conducted a prospective observational study of this protocol and used the LABScreen Single Antigen assay to detect DSA after transplantation. We compared the incidence of acute rejection, lymphocytic bronchiolitis, and bronchiolitis obliterans syndrome (BOS) between those who developed DSA and those who did not using Cox proportional hazards models. We used the Kaplan-Meier method to compare freedom from BOS and survival between those who had persistent DSA and those who had successful depletion of DSA. RESULTS: Among 116 recipients screened, DSA developed in 65 during the study period. Those who developed DSA and received antibody-directed therapy had a similar incidence of acute rejection, lymphocytic bronchiolitis, and BOS as those who did not develop DSA. Furthermore, recipients who had successful depletion of DSA had greater freedom from BOS and better survival than those who had persistent DSA. Finally, those treated for DSA had a similar incidence of infectious complications as those who did not develop DSA. CONCLUSIONS: The development of DSA is surprisingly common after lung transplantation. Antibody-directed therapy may reduce the risk of rejection associated with DSA, but a randomized controlled trial is necessary to critically evaluate the efficacy of this treatment protocol. Copyright 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Authors: Marc Estenne; Janet R Maurer; Annette Boehler; James J Egan; Adaani Frost; Marshall Hertz; George B Mallory; Gregory I Snell; Samuel Yousem Journal: J Heart Lung Transplant Date: 2002-03 Impact factor: 10.247
Authors: Alin L Girnita; Kenneth R McCurry; Aldo T Iacono; Rene Duquesnoy; Timothy E Corcoran; Mohamed Awad; Kathy J Spichty; Samuel A Yousem; Gilbert Burckart; James H Dauber; Bartley P Griffith; Adriana Zeevi Journal: J Heart Lung Transplant Date: 2004-10 Impact factor: 10.247
Authors: Alin L Girnita; Rene Duquesnoy; Samuel A Yousem; Aldo T Iacono; Timothy E Corcoran; Manuela Buzoianu; Bruce Johnson; Kathy J Spichty; James H Dauber; Gilbert Burckart; Bartley P Griffith; Kenneth R McCurry; Adriana Zeevi Journal: Am J Transplant Date: 2005-01 Impact factor: 8.086
Authors: S A Yousem; G J Berry; P T Cagle; D Chamberlain; A N Husain; R H Hruban; A Marchevsky; N P Ohori; J Ritter; S Stewart; H D Tazelaar Journal: J Heart Lung Transplant Date: 1996-01 Impact factor: 10.247
Authors: S Sundaresan; T Mohanakumar; M A Smith; E P Trulock; J Lynch; D Phelan; J D Cooper; G A Patterson Journal: Transplantation Date: 1998-03-15 Impact factor: 4.939
Authors: M A Smith; S Sundaresan; T Mohanakumar; E P Trulock; J P Lynch; D L Phelan; J D Cooper; G A Patterson Journal: J Thorac Cardiovasc Surg Date: 1998-11 Impact factor: 5.209
Authors: Scott M Palmer; R Duane Davis; Denis Hadjiliadis; Marshall I Hertz; David N Howell; Fran E Ward; Kay Savik; Nancy L Reinsmoen Journal: Transplantation Date: 2002-09-27 Impact factor: 4.939
Authors: V G Valentine; R C Robbins; G J Berry; H R Patel; H Reichenspurner; B A Reitz; J Theodore Journal: J Heart Lung Transplant Date: 1996-04 Impact factor: 10.247
Authors: M Gunasekaran; Z Xu; D K Nayak; M Sharma; R Hachem; R Walia; R M Bremner; M A Smith; T Mohanakumar Journal: Am J Transplant Date: 2016-07-16 Impact factor: 8.086
Authors: Deepak K Nayak; Fangyu Zhou; Min Xu; Jing Huang; Moriya Tsuji; Jinsheng Yu; Ramsey Hachem; Andrew E Gelman; Ross M Bremner; Michael A Smith; Thalachallour Mohanakumar Journal: Sci Transl Med Date: 2017-07-12 Impact factor: 17.956
Authors: Laurie D Snyder; Ziwei Wang; Dong-Feng Chen; Nancy L Reinsmoen; C Ashley Finlen-Copeland; W Austin Davis; David W Zaas; Scott M Palmer Journal: Chest Date: 2013-07 Impact factor: 9.410
Authors: Abanti Chaudhuri; Mikki Ozawa; Matthew J Everly; Robert Ettenger; Vikas Dharnidharka; Mark Benfield; Robert Mathias; Anthony Portale; Ruth McDonald; William Harmon; David Kershaw; V Matti Vehaskari; Elaine Kamil; H Jorge Baluarte; Bradley Warady; Li Li; Tara K Sigdel; Szu-chuan Hsieh; Hong Dai; Maarten Naesens; Janie Waskerwitz; Oscar Salvatierra; Paul I Terasaki; Minnie M Sarwal Journal: J Am Soc Nephrol Date: 2013-02-28 Impact factor: 10.121